Piperacillin-tazobactam in pediatric cancer patients younger than 25 months: A retrospective multicenter survey

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 26, Issue 11, 2007, Pages 801-806

  Simon, A ^a   Lehrnbecher, T ^b   Bode, U ^a   Groll, A H ^c   Tramsen, L ^b   Wieland, R ^d   Molitor, E ^a   Fleischhack, G ^a   Laws, H J ^e  

^a UNIVERSITY OF BONN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; GENTAMICIN; GLYCOPEPTIDE; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

ALLERGIC REACTION; ARTICLE; CANCER PATIENT; CHEMOTHERAPY; DATA ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEBRILE CONVULSION; FEBRILE NEUTROPENIA; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; INFANT; IRRITABILITY; MAJOR CLINICAL STUDY; METHODOLOGY; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; WHEEZING;

BACTERIAL INFECTIONS; FEVER OF UNKNOWN ORIGIN; HUMANS; HYPERSENSITIVITY; INFANT; INFANT, NEWBORN; NEOPLASMS; NEUTROPENIA; PENICILLANIC ACID; PIPERACILLIN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 35348877241     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-007-0382-5     Document Type: Article

References (30)

1. Gaur AH, Flynn PM, Shenep JL (2004) Optimum management of pediatric patients with fever and neutropenia. Indian J Pediatr 71:825-835
2. Fleischhack G, Hartmann C, Simon A, Wulff B, Havers W, Marklein G, Hasan C, Bode U (2001) Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother 47:841-853
3. Simon A, Groger N, Wilkesmann A, Hasan C, Wiszniewsky G, Engelhart S, Kramer MH, Bode U, Ammann RA, Fleischhack G (2006) Restricted use of glycopeptides in paediatric cancer patients with fever and neutropenia. Int J Antimicrob Agents 28:417-422
4. Adam D, Linglöf T, Floret D, Kirsch T (2001) Piperacillin/Tazobactam versus Cefotaxime plus metronidazole for the treatment of severe intraabdominal infection in hospitalized pediatric patients. Current Therapeutic Research 62:488-502
5. Maltezou HC, Nikolaidis P, Lebesii E, Dimitriou L, Androulakakis E, Kafetzis DA (2001) Piperacillin/Tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 20:643-646
6. Le Guyader N, Auvrignon A, Vu-Thien H, Portier E, Tabone MD, Leverger G (2004) Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children. Support Care Cancer 12:720-724
7. Fleischhack G, Schmidt-Niemann M, Wulff B, Havers W, Marklein G, Hasan C, Bode U (2001) Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients. Support Care Cancer 9:372-379
8. Bohme A, Shah PM, Stille W, Hoelzer D (1998) Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res 3:324-330
9. Gorschluter M, Hahn C, Fixson A, Mey U, Ziske C, Molitor E, Horre R, Sauerbruch T, Marklein G et al (2003) Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison. Support Care Cancer 11:362-370
10. Hess U, Bohme C, Rey K, Senn HJ (1998) Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Support Care Cancer 6:402-409
11. Kelsey SM, Weinhardt B, Pocock CE, Shaw E, Newland AC (1992) Piperacillin/tazobactam plus gentamicin as empirical therapy for febrile neutropenic patients with haematological malignancy. J Chemother 4:281-285
12. Micozzi A, Nucci M, Venditti M, Gentile G, Girmenia C, Meloni G, Martino P (1993) Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/ teicoplanin in the empirical treatment of neutropenic patients. Eur J Clin Microbiol Infect Dis 12:1-8
13. Reich G, Cornely OA, Sandherr M, Kubin T, Krause S, Einsele H, Thiel E, Bellaire T, Dorken B, Maschmeyer G (2005) Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. Br J Haematol 130:265-270
14. Rossini F, Terruzzi E, Verga L, Larocca A, Marinoni S, Miccolis I, Giltri G, Isella M, Parma M, Pogliani EM (2005) A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia. Support Care Cancer 13:387-392
15. Cornely OA, Wicke T, Seifert H, Bethe U, Schwonzen M, Reichert D, Ullmann AJ, Karthaus M, Breuer K et al (2004) Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. Int J Hematol 79:74-78
16. Bow EJ, Rotstein C, Noskin GA, Laverdiere M, Schwarer AP, Segal BH, Seymour JF, Szer J, Sanche S (2006) A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 43:447-459
17. Perry CM, Markham A (1999) Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs 57:805-843
18. Glasmacher A, von Lilienfeld-Toal M, Schulte S, Hahn C, Schmidt-Wolf IG, Prentice A (2005) An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect 11:17-23
19. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP (1995) Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 39:445-452
20. Nurnberger W, Bonig H, Burdach S, Gobel U (1998) Tolerability of piperacillin/tazobactam in children and adolescents after high dose radio-/chemotherapy and autologous stem cell transplantation. Infection 26:65-67
21. Berger A, Kretzer V, Apfalter P, Rohrmeister K, Zaknun D, Pollak A (2004) Safety evaluation of piperacillin/tazobactam in very low birth weight infants. J Chemother 16:166-171
22. Flidel-Rimon O, Friedman S, Gradstein S, Bardenstein R, Shinwell ES (2003) Reduction in multiresistant nosocomial infections in neonates following substitution of ceftazidime with piperacillin/tazobactam in empiric antibiotic therapy. Acta Paediatr 92:1205-1207
23. Pillay T, Pillay DG, Adhikari M, Sturm AW (1998) Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates. Am J Perinatol 15:47-51
24. Isenberg H (2004) Clinical microbiology procedures handbook, 2nd edn. ASM Press, Cleveland
25. Simon A, Fleischhack G, Hasan C, Bode U, Engelhart S, Kramer MH (2000) Surveillance for nosocomial and central line-related infections among pediatric hematology-oncology patients. Infect Control Hosp Epidemiol 21:592-596
26. Aksoylar S, Cetingul N, Kantar M, Karapinar D, Kavakli K, Kansoy S (2004) Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children. Pediatr Hematol Oncol 21:115-123
27. Malanga CJ, Kokontis L, Mauzy S (1997) Piperacillin-induced seizures. Clin Pediatr (Phila) 36:475-478
28. Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18:657-686
29. Wilcox MH, Freeman J, Fawley W, MacKinlay S, Brown A, Donaldson K, Corrado O (2004) Long-term surveillance of cefotaxime and piperacillin- tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother 54:168-172
30. Winston LG, Charlebois ED, Pang S, Bangsberg DR, Perdreau-Remington F, Chambers HF (2004) Impact of a formulary switch from ticarcillin-clavulanate to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci. Am J Infect Control 32:462-469